Allergic rhinitis is an IgE-mediated inflammatory disease of the nasal mucosa triggered by environmental allergens, causing sneezing, rhinorrhea, nasal congestion, and itching.
Needle-free allergy therapy is forecast to expand through 2035 as self-administered options gain share. House dust mite allergy treatment is projected to grow from $3.18 billion in 2025 to $8.75 billion by 2033.
Allergic rhinitis demonstrates both protective and risk associations with COVID-19 symptoms, while sublingual immunotherapy modifies respiratory and fever outcomes in patients with the condition.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07588672 |
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis |
NOT_YET_RECRUITING | NA |
| NCT07556393 |
Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis |
COMPLETED | PHASE2 |
| NCT07435714 |
Facilitating Surgical Choice in Patient With Chronic Hypertrophic Rhinitis Using a Patient Decision Aid |
RECRUITING | NA |
| NCT07212530 |
EmoTIChealth: Promoting Adolescent Health Through a Serious Game. |
RECRUITING | NA |
| NCT05919316 |
The Efficacy Of Rhinophototherapy Compared To Intranasal Corticosteroids On The Nasal Mucosa |
COMPLETED | NA |
| NCT05208528 |
Effect of the Probiotic ES1 and Its Inactivated Form (HT-ES1) Over Symptomatology Asociated With Allergic Rhinitis |
COMPLETED | NA |
